The impact of traumatic brain injury (TBI) involves a combination of complex biochemical processes beginning with the initial insult and lasting for days, months and even years post-trauma. These changes range from neuronal integrity losses to neurotransmitter imbalance and metabolite dysregulation, leading to the release of pro-or anti-apoptotic factors which mediate cell survival or death. Such dynamic processes affecting the brain's neurochemistry can be monitored using a variety of neuroimaging techniques, whose combined use can be particularly useful for understanding patient-specific clinical trajectories. Here, we describe how TBI changes the metabolism of essential neurochemical compounds, summarize how neuroimaging approaches facilitate the study of such alterations, and highlight promising ways in which neuroimaging can be used to investigate post-TBI changes in neurometabolism.
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The Injured Human Brain
Traumatic brain injury (TBI, see Glossary) is a physical insult to the brain caused by a blunt mechanical force. TBI demographics are staggering: in the USA alone, over 1.4 million cases are recorded every year [1, 2] , whereas annual estimates of sports-related concussions range from 1.6 to 3.8 million (males being about twice as likely to be affected as females) [1] . Long-term effects of TBI include an increased vulnerability to psychiatric and neurological disorders. For example, the risk factor for clinical depression is 1.5 times higher in TBI survivors compared to the general population. Furthermore, for Alzheimer disease (AD) this risk increases to 2.3 and 4.5 times higher, depending on whether the TBI is moderate or severe, respectively [3] .
Throughout the past few decades, the study of TBI using imaging techniques has garnered an increasing amount of attention from health care professionals, policy makers and the public [4] . This is partly because neuroimaging has led to substantial improvement in our understanding of how TBI can affect brain metabolism even years after injury, particularly in cases where immediate sequelae seem modest, long-term consequences seem unrelated to TBI, or both. Recent advances in the neuroimaging of metabolic compounds have made the study of TBIrelated changes in brain function more accessible using noninvasive or minimally-invasive techniques such as magnetic resonance (MR) imaging (MRI), functional MRI (fMRI), magnetic resonance spectroscopy (MRS), diffusion weighted imaging (DWI), diffusion tensor imaging (DTI), single-photon emission computed tomography (SPECT) and positron emission tomography (PET; Figure 1 ). The combined use of these techniques has greatly furthered scientific knowledge of post-traumatic changes in neurochemistry and neurophysiology [5] . Nevertheless, substantial additional progress is needed to bridge the gap between the insights which these modalities can deliver regarding human TBI -on the one hand -and the level of sophistication Trends TBI is thought to result in a 'metabolic crisis' which must be managed as soon as possible following injury.
Measuring TBI-related change over time using multimodal imaging informs the basic scientific knowledge concerning altered brain metabolic processes.
Differing neuroimaging methods measure varying aspects of the TBI timeline. No single modality is likely to capture it all or be predictive of outcome, per se.
Animal models, while useful, are insufficient for fully understanding injury in humans due to differences in brain morphometry, immune responses, and metabolism.
Multimodal neuroimaging in TBI necessitates novel data processing and analytic considerations but can guide new research aimed at identifying novel targets for pharmacological treatment as well as biomarkers predictive of cell survival/death. 
